Sign Out
Patients with Hunter syndrome (Mycopolysaccharidosis II, MPS II). Elaprase has been shown to improve walking capacity in patients ≥5 years.
In patients 16 months to 5 years, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with Elaprase has reduced spleen volume similarly to that of adults and children ≥5 years.
The safety and efficacy of Elaprase have not been established in pediatric patients <16 months (see Precautions).
Continue with Google